Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Aptevo leans on TP53 leukaemia signal as it eyes 2027 regulators with $8.3m in cash

Early RAINIER data for mipletamig plus venetoclax and azacitidine give the small-cap a story to take to regulators, but its balance sheet remains thin.

16 Nov 2026 · Aptevo Therapeutics Inc. APVO · Company news

Aptevo Therapeutics is pointing to a response signal in one of acute myeloid leukaemia's hardest genetic subgroups as it tries to move mipletamig towards a regulatory conversation. The company's third-quarter update, dated 16 November 2026, paired its financial results with fresh data from the Phase 1b RAINIER study in frontline AML.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Aptevo Therapeutics Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →